February 24, 2017 08:49 AM ESTUpdated 09:06 AM
News Briefing

As­traZeneca gets a thumbs-up for ZS-9 in Eu­rope; Toca­gen wins a BTD for brain can­cer drug

Shehla Shakoor

Managing Director

• As­traZeneca has won a rec­om­men­da­tion for its close­ly-watched hy­per­kalemia drug ZS-9 from the EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use. As­traZeneca bought …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

A service from the Financial Times